DMTs may reduce risk for becoming wheelchair dependent in patients with PPMS

In patients with primary progressive MS who experience persistent inflammatory activity, disease-modifying therapies were linked to a reduced risk for becoming wheelchair dependent, according to a study in JAMA Neurology.
“Although several disease-modifying treatments are available for the treatment of relapsing-remitting MS, in the PPMS phenotype, with the exception of ocrelizumab, previous randomized clinical trials of current licensed [disease-modifying therapies] were found to be ineffective,” Emilio Portaccio, MD, of the department of neuroscience, psychology, pharmacology and

In patients with primary progressive MS who experience persistent inflammatory activity, disease-modifying therapies were linked to a reduced risk for becoming wheelchair dependent, according to a study in JAMA Neurology.
“Although several disease-modifying treatments are available for the treatment of relapsing-remitting MS, in the PPMS phenotype, with the exception of ocrelizumab, previous randomized clinical trials of current licensed [disease-modifying therapies] were found to be ineffective,” Emilio Portaccio, MD, of the department of neuroscience, psychology, pharmacology and